These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31887474)

  • 1. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
    Zhang B; Zhang Q; Xiao Z; Sun X; Yang Z; Gu Q; Liu Z; Xie T; Jin Q; Zheng P; Xu S; Zhu W
    Bioorg Chem; 2020 Jan; 95():103525. PubMed ID: 31887474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
    Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
    Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
    Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
    Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors.
    Yu L; Wang Q; Wang C; Zhang B; Yang Z; Fang Y; Zhu W; Zheng P
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31547116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
    Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
    Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
    Yang Y; Sun X; Luo L; Peng R; Yang R; Cheng Z; Lv Y; Li H; Tang Q; Zhu W; Qiao D; Xu S
    Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
    Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
    Lei F; Sun C; Xu S; Wang Q; OuYang Y; Chen C; Xia H; Wang L; Zheng P; Zhu W
    Eur J Med Chem; 2016 Jun; 116():27-35. PubMed ID: 27043268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
    Liao W; Wang Z; Han Y; Qi Y; Liu J; Xie J; Tian Y; Lei Q; Chen R; Sun M; Tang L; Gong G; Zhao Y
    Eur J Med Chem; 2020 Jul; 197():112309. PubMed ID: 32375077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.
    Gao H; Li Z; Wang K; Zhang Y; Wang T; Wang F; Xu Y
    Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.
    Peterson EA; Andrews PS; Be X; Boezio AA; Bush TL; Cheng AC; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Harmange JC; Kim JL; Mullady EL; Olivieri P; Schenkel LB; Stanton MK; Teffera Y; Whittington DA; Cai T; La DS
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2064-70. PubMed ID: 21376583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
    Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors.
    Zhan M; Deng Y; Zhao L; Yan G; Wang F; Tian Y; Zhang L; Jiang H; Chen Y
    J Med Chem; 2017 May; 60(9):4023-4035. PubMed ID: 28409639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
    Liu Y; Xia Q; Fang L
    Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor.
    Wang HY; Shen Y; Zhang H; Hei YY; Zhao HY; Xin M; Lu SM; Zhang SQ
    Future Med Chem; 2018 Oct; 10(20):2445-2455. PubMed ID: 30325235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.